In context to EBV-specific CD4+ T cells responses, our data are consistent with previous studies in patients with EBV-associated PTLD, showing considerably increased CD8+ T-cell responses but only a moderate increase of CD4+ T-cell responses after reduction in immunosuppression and rituximab treatment (35). This evidence concerns the gene CD4 and post-transplant lymphoproliferative disease.